Rv0652-treated DCs pulsed with OVA_257–264 protects mice against E.G7 tumor challenge.

<p>C57BL/6 mice were challenged s.c with 3×10⁵ E.G7 or EL4 tumor cells into the right flank area. For administration of DCs (1×10⁶ cells/mice), mice were injected intravenously with PBS, iDC, DCs-OVA (DCs pulsed with OVA_257–264), Rv0652-DCs-OVA (Rv0652-treated DCs pulsed with OVA_257–264), or LPS-DCs-OVA (LPS-treated DCs pulsed with OVA_257–264) on days 1, 3 and 5 after the tumor challenge. Following the tumor challenge with E.G7 (A) and EL4 (B), tumor growth was monitored by measuring the diameter of the tumor every 2 days. **<i>P</i><0.01, each group, n = 10. (C) Survival of mice with an E.G7 tumor challenge after injection of OVA peptide-pulsed and Rv0652-treated DCs, n = 10 mice/group. <i>P</i> value calculated by Kaplan-Meyer log-rank test between two groups of mice injected with DCs-OVA and Rv0652-DCs-OVA, respectively.